Abstract Background The therapeutic strategy for MM/SM1 oesophageal superficial cancer (OSC) after endoscopic submucosal dissection (ESD) still remains controversial, but there are some opinions that cut-end positive, vascular invasion positive, infiltrative growth pattern (INF) c, and poorly differentiated carcinoma are the risk factors for the recurrence of lymph-node (LN) or distal metastases. Methods This study aimed to investigate the recurrence and prognosis after ESD in patients with MM/SM1 OSC who do not have the risk factors. We performed ESD in 167 patients with OSC, and among these, we enrolled 15 patients with MM/SM1 OSC who did not have cut-end positive, vascular invasion positive, INF c, or poorly differentiated carcinoma in this study. The clinical background characteristics, endoscopic findings, additional therapy after ESD, recurrence, and prognosis of these patients were investigated. Results The median age of the patients, including 11 males and 4 females, was 69 years (range: 59–84). The mean follow-up duration was 75 months (range: 17-137). Of these, 3 patients had chronic obstructive pulmonary disease, 1 had cerebrovascular disease, and 1 had chronic heart failure. Regarding the lesion location, 2 patients had the lesion at Ut, 11 had at Mt, and 2 had at Lt. In 3 patients, the lesion occupied more than 3/4 of the lumen. We found 2 patients with elevated-type lesions, 10 with flat-type lesions, and 3 with depressed-type lesions. The mean long diameter of the lesions was 29 mm (range: 11-47). Regarding the lesion depth, there were 12 lesions in MM and 3 lesions in SM1. A total of 4 patients received additional radiation therapy, and the remaining 11 patients were followed up without additional therapy. The patients who received additional therapy did not have recurrences; however, 4 among the 11 patients without additional therapy manifested LN and lung metastases. Furthermore, 3 patients died because of the progression of oesophageal cancer, and another patient received chemotherapy. Conclusion In this study we showed that follow-up without additional therapy after ESD in patients with MM/SM1 OSC is unlikely to be acceptable despite not having risk factors. Therefore, we should urgently develop a treatment strategy for patients with MM/SM1 OSC after ESD.